Study of Drug 1 (Enzalutamide) Plus Drug 2 (Relacorilant) for Patients With Prostate Cancer

Part of paid clinical trials in Chicago, Illinois.

Sponsor
University of Chicago
Study ID
NCT03674814
Phase
PHASE1
Status
Completed

Conditions

Eligibility Criteria

Sex
MALE
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Enzalutamide — DRUG
    Enzalutamide will be taken by mouth at assigned dose. Enzalutamide will be obtained as standard of care prescription (not provided by study).
  • Relacorilant — DRUG
    Relacorilant will be taken by mouth at assigned dose. Relacorilant will be provided by the study.

Study Details

The study is an open-label Phase 1 study of the combination of relacorilant with enzalutamide in patients with metastatic castration resistant prostate cancer (mCRPC).

Key Dates

First listed
Sep 18, 2018
Start date
Oct 23, 2018
Status verified
Mar 2026
Primary completion
Jun 10, 2024
Completion
Jun 10, 2024

Study Design

Enrollment
42 participants (actual)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Dose Level
    Relacorilant will be given at a dose once daily. Enzalutamide will be given at a dose once daily.

Primary Outcome Measure

Number of Participants With Treatment-Related Adverse Events as Assessed by CTCAE v4.0 [ Time Frame: 28 days after start of dosing ]

Locations (1)

FacilityCityStateZIPSite coordinators
University Of Chicago Medicine Comprehensive Cancer CenterChicagoIllinois60637-

Find similar trials in Chicago, IL

By condition
Prostate cancer
By specialty
OncologyProstate oncologyMen's healthUrology
By research site
University Of Chicago Medicine Comprehensive Cancer Center· Chicago, IL

Related Studies